Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
74.41
-0.14 (-0.19%)
Sep 19, 2025, 4:00 PM EDT - Market closed
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.53B in the quarter ending June 30, 2025, with 11.89% growth. This brings the company's revenue in the last twelve months to $5.69B, up 9.14% year-over-year. In the year 2024, Edwards Lifesciences had annual revenue of $5.44B with 8.57% growth.
Revenue (ttm)
$5.69B
Revenue Growth
+9.14%
P/S Ratio
7.73
Revenue / Employee
$359,816
Employees
15,800
Market Cap
43.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EW News
- 22 days ago - Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care - Business Wire
- 4 weeks ago - Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase - Business Wire
- 5 weeks ago - Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 6 weeks ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 6 weeks ago - JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition - GlobeNewsWire
- 6 weeks ago - FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - Reuters
- 6 weeks ago - Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve - Business Wire
- 6 weeks ago - Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga